Early Decisions That Matter: Managing Smoldering and Newly Diagnosed Myeloma | Rafat Abonour, MD
HealthTree Foundation for Multiple Myeloma
790 views
Thanks to our Roundtable Sponsors for their support:
Kite | ARCELLX , Johnson & Johnson, Pfizer, Bristol Myers Squibb, GSK, and Adaptive Biotechnologies.
What are the most important early treatment decisions for patients with smoldering multiple myeloma and newly diagnosed multiple myeloma? In this informative discussion, Rafat Abonour explains how early choices in monitoring, risk assessment, and treatment planning can have a major impact on long-term outcomes and quality of life.
Recorded at the HealthTree Multiple Myeloma RoundTable in Miami, Rafat Abonour, MD, discusses the potential treatment options for Smoldering Multiple Myeloma patients.
In this educational session, Dr. Abonour explains the differences between Smoldering Multiple Myeloma and Multiple Myeloma and presents studies related to early treatment of Smoldering Myeloma.
If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/6286...
For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!
Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_so...
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.
1 Comments
Early Decisions That Matter: Managing Smoldering and Newly Diagnosed Myeloma | Rafat Abonour, MD
HealthTree Foundation for Multiple Myeloma
790 views
Thanks to our Roundtable Sponsors for their support:
Kite | ARCELLX , Johnson & Johnson, Pfizer, Bristol Myers Squibb, GSK, and Adaptive Biotechnologies.
What are the most important early treatment decisions for patients with smoldering multiple myeloma and newly diagnosed multiple myeloma? In this informative discussion, Rafat Abonour explains how early choices in monitoring, risk assessment, and treatment planning can have a major impact on long-term outcomes and quality of life.
Recorded at the HealthTree Multiple Myeloma RoundTable in Miami, Rafat Abonour, MD, discusses the potential treatment options for Smoldering Multiple Myeloma patients.
In this educational session, Dr. Abonour explains the differences between Smoldering Multiple Myeloma and Multiple Myeloma and presents studies related to early treatment of Smoldering Myeloma.
If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/6286...
For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!
Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_so...
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.